Cargando…

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis

Acute myeloid leukemia (AML) is an aggressive stem cell malignancy that is difficult to treat. There are limitations to the current treatment regimes especially after disease relapse, and therefore new therapeutic agents are urgently required which can overcome drug resistance whilst avoiding unnece...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dijk, Marianne, Murphy, Eoin, Morrell, Ruth, Knapper, Steven, O'Dwyer, Michael, Samali, Afshin, Szegezdi, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756416/ https://www.ncbi.nlm.nih.gov/pubmed/24212664 http://dx.doi.org/10.3390/cancers3011329

Ejemplares similares

Targeting AML through DR4 with a novel variant of rhTRAIL
por: Szegezdi, Eva, et al.
Publicado: (2011)

Stem cells are resistant to TRAIL receptor-mediated apoptosis
por: Szegezdi, Eva, et al.
Publicado: (2009)

TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt
por: Szegezdi, E, et al.
Publicado: (2006)

Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML
por: O’ Reilly, Eimear, et al.
Publicado: (2018)

Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways
por: van Dijk, M, et al.
Publicado: (2013)

Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines
por: Mahalingam, D, et al.
Publicado: (2009)

The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL-induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells
por: NATHWANI, SEEMA-MARIA, et al.
Publicado: (2016)

Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL
por: Szegezdi, Eva, et al.
Publicado: (2012)

Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells
por: Jiang, Lei, et al.
Publicado: (2021)

Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL
por: Bui, Hang Thi Thuy, et al.
Publicado: (2019)

An added dimension to tumour TRAIL sensitivity
por: Healy, Sandra, et al.
Publicado: (2015)

Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
por: Wu, Yi-Xin, et al.
Publicado: (2016)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems
por: Alizadeh Zeinabad, Hojjat, et al.
Publicado: (2022)

Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL
por: Reeve, Janice LV, et al.
Publicado: (2007)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
por: Cerruti, Fulvia, et al.
Publicado: (2017)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
por: Dufour, Florent, et al.
Publicado: (2016)

Inhibition of IRE1α RNase activity sensitizes patient‐derived acute myeloid leukaemia cells to proteasome inhibitors
por: Creedican, Stuart, et al.
Publicado: (2022)

Cytokine-induced β-cell apoptosis is NO-dependent, mitochondria-mediated and inhibited by BCL-X(L)
por: Holohan, C, et al.
Publicado: (2008)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells
por: Ryu, Sunhyo, et al.
Publicado: (2018)

Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells
por: Mahalingam, D, et al.
Publicado: (2010)

Apoptosis: a mapped path to cell death
por: Samali, Afshin
Publicado: (2007)

Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy
por: Galiègue‐Zouitina, Sylvie, et al.
Publicado: (2021)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Mechanisms of ER Stress-Mediated Mitochondrial Membrane Permeabilization
por: Gupta, Sanjeev, et al.
Publicado: (2010)

Nerve growth factor blocks thapsigargin-induced apoptosis at the level of the mitochondrion viaregulation of Bim
por: Szegezdi, E, et al.
Publicado: (2008)

[Retracted] Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL‑mediated apoptosis
por: Yoshiba, Sayaka, et al.
Publicado: (2023)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231
por: Krętowski, Rafał, et al.
Publicado: (2014)

Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line
por: Krętowski, Rafał, et al.
Publicado: (2014)

Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System
por: Sarhan, Dhifaf, et al.
Publicado: (2014)

Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link
por: Fulda, Simone
Publicado: (2011)

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants
por: Reis, C R, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_b5f57h4peuddrgk58nsfrmjojb